Buprenorphine Sublingual Tablets Recalled for Manufacturing Quality Deviations
Sun Pharmaceutical recalls 12,336 bottles of Buprenorphine 8 mg sublingual tablets (Lot DND1515A) due to Good Manufacturing Practice deviations identified during manufacturing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary precautionary recall. The rubric identifies voluntary precautionary recalls as Moderate severity. No illnesses, injuries, or adverse events are documented in the source.
Plain-English summary
Sun Pharmaceutical Industries Inc. is recalling 12,336 bottles of Buprenorphine 8 mg sublingual tablets due to Good Manufacturing Practice (CGMP) deviations identified during the manufacturing process. The affected lot is DND1515A with an expiration date of August 2024. Buprenorphine is a prescription opioid medication used to treat opioid use disorder.
The CGMP deviations were identified by the manufacturer, which voluntarily initiated this recall on May 3, 2023. The product was distributed to 19 distributors across the United States. The recall was terminated on January 9, 2024.
Patients currently taking buprenorphine should verify their medication lot number and contact their healthcare provider or pharmacist if they possess the recalled lot. Healthcare providers and dispensing pharmacies should verify whether their patients or inventory includes the recalled lot DND1515A and provide appropriate guidance to affected patients.
The recalled product
- Product
- BUPRENORPHINE (BUPRENORPHINE)
- Brand
- BUPRENORPHINE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Category
- Drug — Prescription Opioid
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: DND1515A
- Exp 08/24
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27